Every Form 4 that Attovia Therapeutics Inc (ATTO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ATTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATTO filings page.
Attovia Therapeutics, Inc. (ATTO) is the subject of an amended Form 4 reporting complex indirect transactions associated with director Colin Walsh and entities affiliated with The Goldman Sachs Group Inc. Series B and C Preferred Stock automatically converted into common stock at a 9.29-for-1 ratio upon the IPO closing on August 6, 2026, eliminating those preferred holdings. Goldman Sachs & Co. LLC, acting as a market maker, reported purchases and sales of common stock and the establishment of long equity swap positions, with any profit potentially recoverable under Section 16(b) to be remitted to Attovia. The amendment also corrects an earlier administrative error in the number of common shares issuable upon conversion, and Walsh disclaims beneficial ownership except to the extent of any pecuniary interest.
Attovia Therapeutics, Inc. (ATTO) reported insider activity by multiple Goldman Sachs–affiliated entities, all listed as former 10% owners. On August 6, 2026, they reported the conversion of Series B and Series C Preferred Stock into common stock, eliminating 18,181,830 Series B and 4,445,275 Series C preferred shares and issuing 1,957,134 and 478,598 common shares, respectively. This corrects an administrative error in an earlier Form 3 and reflects automatic conversion upon the IPO after a 1‑for‑9.29 reverse stock split.
On the same date, an affiliated entity purchased 500,000 common shares at $17.00 per share. On August 5, 2026, Goldman Sachs & Co. LLC, acting as a market maker, purchased 85,000 shares, sold 105,807 shares, and entered into long equity swap positions referencing 105,807 shares at prices around $21.22–$21.27. The reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest, and any Section 16(b) profit from the market‑making trades will be remitted to Attovia.
Attovia Therapeutics, Inc. director Colin Walsh, affiliated with Goldman Sachs entities, reported the automatic conversion of 22,627,105 shares of Series B and C Preferred Stock into common stock on a 9.29-for-1 basis upon the company’s IPO closing on August 6, 2026, with no cash consideration. The resulting common shares are held indirectly through multiple Goldman Sachs-managed investment vehicles, and Walsh disclaims beneficial ownership beyond any pecuniary interest. On August 5–6, 2026, Goldman Sachs & Co. LLC, acting as a market maker, purchased 585,000 ATTO common shares (including 500,000 at $17.00 and 85,000 at $21.00) and sold 105,807 shares around $21–22 per share; any profit recoverable under Section 16(b) will be remitted to Attovia.
Goldman Sachs–affiliated entities reported multiple transactions in Attovia Therapeutics common stock and preferred stock. On completion of Attovia’s IPO, all redeemable convertible preferred stock automatically converted into common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split, and prior Form 3 conversion figures were corrected. GS&Co, acting as a market maker, bought 85,000 shares and sold 105,807 shares of common stock on August 5, 2026, and additional common shares were purchased in the IPO by affiliated investment vehicles.
Attovia Therapeutics, Inc. insider Deep Track Biotechnology Master Fund, Ltd. reported the automatic conversion of Series C Redeemable Convertible Preferred Stock into common stock in connection with the closing of Attovia’s initial public offering. 18,181,818 preferred shares converted into 1,957,138 common shares at a 9.29-for-one ratio, resulting in 1,957,138 common shares held directly. Deep Track Capital, LP and David Kroin may be deemed beneficial owners through their roles but each disclaims beneficial ownership beyond their respective pecuniary interests.
venBio Global Strategic Fund IV, L.P., a 10% owner of Attovia Therapeutics, Inc., reported multiple equity transactions tied to Attovia’s initial public offering. On August 6, 2026, the fund converted 21,477,273 Series A, 7,636,362 Series B, and 6,179,219 Series C Preferred Stock shares into Common Stock as part of an automatic conversion at IPO, as adjusted for a 1-for-9.29 reverse stock split effective July 29, 2026. The filing also reports an additional open-market purchase of 382,352 Common Stock shares at $17.00 per share. These securities are held directly by venBio Global Strategic Fund IV, L.P.; its general partner entities and members disclaim beneficial ownership beyond their pecuniary interest.
Attovia Therapeutics, Inc. reported insider activity by investment entities associated with Redmile Group and Jeremy Green as ten percent owners. On August 6, 2026, 782,854 shares of Series B Preferred Stock automatically converted in full into the same number of common shares upon completion of Attovia’s IPO for no consideration. On the same date, Redmile-managed vehicles purchased an additional 600,000 shares of common stock at $17.00 per share in the IPO, including a 200,000-share direct purchase that brought one reported direct common position to 982,854 shares. The filing notes that Redmile and Jeremy Green may be deemed beneficial owners through their roles as manager and principal, while disclaiming beneficial ownership beyond any pecuniary interest.
Frazier Life Sciences XI, L.P., together with affiliated general partners FHMLS XI, L.P. and FHMLS XI, L.L.C., reported multiple conversions of preferred stock in Attovia Therapeutics, Inc. On August 6, 2026, Series A‑1, A‑2, B and C Preferred Stock automatically converted into Common Stock on a 9.29:1 basis immediately upon closing of Attovia’s initial public offering, eliminating these preferred positions. In connection with these automatic conversions, Frazier received blocks of Attovia Common Stock, all held directly by Frazier Life Sciences XI, L.P. In a separate transaction the same day, Frazier purchased 588,235 shares of Attovia Common Stock at $17.00 per share in an open‑market or private transaction, increasing its Common Stock holdings; post‑transaction Common Stock balances are not specified in this report.
Attovia Therapeutics director Angie You received a grant of stock options for 27,000 shares of common stock. The options have an exercise price of $17.00 per share and expire on August 3, 2036. According to the terms, the options vest in full on the earlier of August 4, 2027 or the next annual stockholders’ meeting, subject to continued service. Following this grant, the reported derivative holdings from this award total 27,000 options held directly.
Attovia Therapeutics, Inc. reported that director Mitchell Gold received a grant of 27,000 stock options to buy common stock at an exercise price of $17.00 per share. The options expire on August 3, 2036. According to the award terms, 25% of the options vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service.
Attovia Therapeutics’ Chief Business Officer, Zaneta Odrowaz, received a grant of stock options for 140,000 shares of common stock on August 4, 2026. The options carry a $17.00 per share exercise price and expire on August 3, 2036. 25% of the options vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service. Following this award, she holds 140,000 stock options directly.
Attovia Therapeutics, Inc. reported that Chief Scientific Officer Petter Veiby received a grant of stock options covering 140,000 shares of common stock at an exercise price of $17.00 per share. The options expire on August 3, 2036 and vest 25% on August 4, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service. Following this award, Veiby holds options on 140,000 shares directly.
Attovia Therapeutics, Inc. reported that Chief Medical Officer Chen Hubert received a grant of stock options covering 140,000 shares of common stock on August 4, 2026. The options have an exercise price of $17.00 per share and expire on August 3, 2036. Following this grant, Hubert holds 140,000 options directly. According to the vesting terms, 25% of the options vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the subsequent 36 months, subject to continued service.
Attovia Therapeutics, Inc. reported a grant of stock options to its Chief Financial Officer. The grant covers 140,000 Stock Options (Right to Buy) with an exercise price of $17.00 per share, expiring on August 3, 2036, and represents 140,000 options held after the transaction. The options relate to an equivalent number of shares of common stock.
According to the vesting terms, 25% of the options will vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, contingent on continued service to the company.
Attovia Therapeutics, Inc. reported a grant of stock options covering 538,300 shares of common stock with an exercise price of $17.00 per share. The options expire on August 3, 2036. According to the vesting schedule, 25% vests on August 4, 2027, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued service.